Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | ALPG | P10696 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | GPR3 | P46089 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30273080 | 1.00 | HPGD (0.60) | HPGDCYP1A2SMN1; SMN2CYP2C19CYP2D6 | |
| SCHEMBL25911478 | 0.90 | CYP1A2 (0.58) | HPGDCYP1A2SMN1; SMN2CYP2C19CYP2D6 | |
| SCHEMBL1520228 | 0.76 | MEN1 (0.64) | HPGDCYP1A2SMN1; SMN2CYP2C19PARP1 | |
| SCHEMBL30273069 | 0.75 | HPGD (0.51) | HPGDCYP1A2SMN1; SMN2CYP2C19CYP2D6 | |
| SCHEMBL8478795 | 0.75 | HPGD (0.44) | HPGDCYP1A2SMN1; SMN2CYP2C19CYP2D6 | |
| SCHEMBL25093447 | 0.75 | PARP1 (0.49) | CYP1A2SMN1; SMN2CYP2C19CYP2D6ALPG | |
| SCHEMBL30018760 | 0.75 | PARP1 (0.49) | CYP1A2SMN1; SMN2CYP2C19CYP2D6ALPG | |
| SCHEMBL30019173 | 0.75 | PARP1 (0.49) | CYP1A2SMN1; SMN2CYP2C19CYP2D6ALPG | |
| SCHEMBL25093456 | 0.75 | PARP1 (0.49) | CYP1A2SMN1; SMN2CYP2C19CYP2D6ALPG | |
| SCHEMBL28935130 | 0.74 | KDM4E (0.57) | HPGDCYP1A2SMN1; SMN2CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117323377-A | Alcohol extract of fructus forsythiae pericarp at golden edge, preparation method and application thereof | 浙江大学 | 2024-01-02 | — | — | CN | disclosed |
| US-6815442-B2 | A PHENOXY-ALKYL-QUINOXALINONE DERIVATIVES FOR INHIBITING DRUG TRANSPORT PROTEINS THAT EFFLUX THERAPEUTIC AGENTS FROM CELLS; SYNERGISTIC | THE PENN STATE RESEARCH FOUNDATION | 2004-11-09 | — | — | US | disclosed |
| US-6693112-B2 | FOR INHIBITING DRUG TRANSPORT FROM TARGET CELLS OR TISSUES IN AN ANIMAL UNDERGOING CHEMOTHERAPY; FOR PREVENTING DRUG RESISTANCE | THE PENNSYLVANIA STATE UNIVERSITY | 2004-02-17 | — | — | US | disclosed |
| US-20030203910-A1 | Novel compounds for enhancing chemotherapy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-30 | — | — | US | disclosed |
| US-20030105122-A1 | Compounds for enhancing chemotherapy | THE PENN STATE RESEARCH FOUNDATION. | 2003-06-05 | — | — | US | disclosed |
| US-6537993-B2 | Compounds for enhancing chemotherapy | PENN STATE RESEARCH FOUNDATION | 2003-03-25 | — | — | US | disclosed |
| EP-1272479-A2 | NOVEL COMPOUNDS FOR ENHANCING CHEMOTHERAPY | THE PENN STATE RESEARCH FOUNDATION (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020013322-A1 | Novel compounds for enhancing chemotherapy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-01-31 | — | — | US | disclosed |
| WO-2001074790-A2 | NOVEL COMPOUNDS FOR ENHANCING CHEMOTHERAPY | THE PENN STATE RESEARCH FOUNDATION (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203910-A1 | Novel compounds for enhancing chemotherapy | ABCB1, ABCB11, ABCC1 | HPGD 2330/4885CYP1A2 3649/4885SMN1; SMN2 4549/4885 |
| US-20020013322-A1 | Novel compounds for enhancing chemotherapy | ABCB1, ABCB11, ABCC1 | HPGD 2330/4885CYP1A2 3649/4885SMN1; SMN2 4549/4885 |
| US-20030105122-A1 | Compounds for enhancing chemotherapy | NQO2, MCL1, ABCB1 | HPGD 682/4885CYP1A2 566/4885SMN1; SMN2 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.